Communiqués Lee's Pharmaceutical Holdings Limited

Actions

950 KYG5438W1116

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:03 26/08/2026			Varia. 5j.	Varia. 1 janv.
1,120 ^HKD	+0,90%		-3,45%	-26,32%

30/07	Ashlins obtient les droits exclusifs de développement et de commercialisation de produits pharmaceutiques intégrant l'interféron de Lee's Pharm	CI
17/07	Lee's Pharmaceutical Holdings Limited conclut un accord exclusif de licence et d'approvisionnement avec Ashlins Ocular Pharmaceuticals, Inc. pour ses produits à base d'interféron alpha-2b hors de la Grande Chine	CI

Communiqués

31/12/21	Listing on Guidance for Family Choice Pharmacy of Lee's Pharm signature products, Ferplex and Yallaferon	AQ
14/05/21	Lee Pharmaceutical : Notice of Board Meeting	PU
29/04/21	Lee Pharmaceutical : (1) Establishment of Management Committee; (2) Resignation of Chief Executive Officer and Re-designation of Director; and (3) Change of Authorised Representative	PU
29/04/21	Lee Pharmaceutical : List of Directors and their Role and Function	PU
29/04/21	Lee Pharmaceutical : Terms of Reference of the Management Committee	PU
28/04/21	Lee Pharmaceutical : Connected Transaction - Provision of Financial Assistance	PU
28/04/21	Lee Pharmaceutical : Update on The Proposed Spin-off and Separate Listing of Zhaoke Ophthalmology Limited on The Main Board of The Stock Exchange - Final Offer Price	PU
21/04/21	Lee Pharmaceutical : General Mandates to Repurchase Shares and to Issue New Shares, Re-election of Directors, and Notice of Annual General Meeting	PU
16/04/21	Lee Pharmaceutical : Update on The Proposed Spin-off and Separate Listing of Zhaoke Ophthalmology Limited on The Main Board of The Stock Exchange - Publication of The Prospectus and Expected Size of The Global Offering and Offer Price Range	PU
12/04/21	Lee Pharmaceutical : Voluntary Announcement - Update on Research and Development of an Investigational Ophthalmology Product of an Associated Company of the Group	PU
07/04/21	Lee Pharmaceutical : Update on The Proposed Spin-off and Separate Listing of Zhaoke Ophthalmology Limited on The Main Board of The Stock Exchange - Post Hearing Information Pack	PU
26/03/21	Lee Pharmaceutical : Connected Transaction - Provision of Financial Assistance	PU
23/03/21	Lee Pharmaceutical : Update on The Proposed Spin-off and Separate Listing of Zhaoke Ophthalmology Limited on The Main Board of The Stock Exchange - Record Date, Closure of Register of Members and Basis of The Assured Entitlement of Qualifying Shareholders in The Preferential Offering	PU
15/03/21	Lee Pharmaceutical : Extraordinary General Meeting Held on 15 March 2021 - Poll Results	PU
11/03/21	Lee Pharmaceutical : Voluntary Announcement - Update on an Investigational Direct Oral Anticoagulant	PU
11/03/21	Lee Pharmaceutical : Voluntary Announcement - Update on an Investigational Ophthalmology Product of an Associated Company of the Group	PU
05/03/21	Lee Pharmaceutical : Voluntary Announcement - Socazolimab Obtained Approval for a Phase III Clinical Trial from NMPA	PU
04/03/21	Lee Pharmaceutical : Voluntary Announcement - Update of Business Development with KPC Pharmaceuticals, Inc.	PU
24/02/21	Lee Pharmaceutical : Proposed Spin-off and Separate Listing of Zhaoke Ophthalmology Limited on The Main Board of The Stock Exchange and Notice of Extraordinary General Meeting	PU
24/02/21	Lee Pharmaceutical : Proxy Form for use by Shareholders at the Extraordinary General Meeting	PU
24/02/21	Lee Pharmaceutical : Notice of Extraordinary General Meeting	PU
10/02/21	Lee Pharmaceutical : Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed from Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China	AQ
26/10/20	Lee's Pharmaceutical Holdings Limited : - Establishment of the Group Commercial Operations Centre	AQ
26/10/20	Lee's Pharmaceutical Holdings Limited : - Grant of Share Options	AQ
21/10/20	Lee's Pharmaceutical Holdings Limited : - Business Update on the In-Licensing and Research and Development of Ophthalmology Products of an Associated Company of the Group	AQ